- NewsCategory：
- All Company news Industry news
common83One result
-
1025
Pliant Therapeutics Announces Strate∑λ₩gic Collaboration to Develop Nov•εel Therapies for NASH and F✘εibrotic Diseases
Pliant Therapeutics Announces Strategic Col♦laboration to Develop Novel₩ ↕' Therapies for NASH and Fibrotic Disea€λ≠ sesTHURSDAY, OCTOBER 2÷' ♠4, 2019Pliant Therapeutics, Inc., a☆♠¥× clinical stage biopharmaceutical ">≥company focused on discovering and developing nov≠☆≤§el therapies for the treatment of fibrosis, to"✘βday announced it has entered into a strategγ₹ic collaboration and" license agreement with Noφ∞¶vartis covering the development€♠ and commercialization of Pliant's preclin<∏ ical product candidate, PLN-14♦$∞↕74 and up to three additional integri¶"π>n targets. PLN-1474 is an in♥¶ternally discovered small molecule♦γ selective inhibitor of integ©☆δrin αVβ1, currently bein≥×$≥g developed for the treatment of liver f₽₹ibrosis associated with nonalcoholi↕βc steatohepatitis (NASH)."Our r≥÷εδesearch continues to ge®£nerate compelling preclinical evidence that> supports the advancement of PLN-1474 as a cl&ε"∑inical candidate and validates o" φ≥ur approach of evaluati✔σ×Ωng αVβ1 integrin inhibition to treat advance←<λd liver fibrosis associated with NASH," said B•→ernard Coulie, M.D., ¶↔" Ph.D., president and chief executive of≤£δficer of Pliant Therapeutic≥s. "Pairing Pliant's leading integrin b→ iology and drug discovery capabilities with Novartis, a world-leader with one of the b×☆±πroadest pipelines inves×✘tigating mono and combination therapies for live™✘∞r diseases including NASH, will support our≠× goal of developing novel ther↕←αapies for fibrotic di₩≠seases and potentially brin≥€g meaningful treatment options to patients." γ→Pliant will initially receive∑₩ $80 million from Novartis,£¶ including an upfront payment in connection withγδφ the collaboration agreement as well as equity inφ✔vestment commitments. The collaboration agree€δment is for a worldwide exclusive license to P₽↑ΩLN-1474 and up to three additio→≥βnal product candidates generated under •♣✘the collaboration. In addition, Novartis will fu₹ nd Pliant's research and development↔↓ activities under the collaboration. Plia©₹≠nt will be responsible for development of PLN-14<₩✔74 through Phase 1 after which No§δ₹☆vartis will assume r₽↕®esponsibility for all future development, manuf&✘♠acturing and commercialization. Pliant is eligφ© ible to earn milestone payments, contingenε☆±t upon the achievement of specified development,∑§ regulatory and commercial milestones.≤₽ The agreement also provides for tiered roσ×yalties payable to Pliant ↕♥∞πranging from the mid-single digits to low d≈≥ouble digits on produ•↓↕ct sales upon commercialφ♣↓ization. The transactΩ≥≠ion is subject to customary closin≠÷ g conditions, including clearance under ₩✔ 'the Hart-Scott-Rodino Antitrust Improveme®↓nts Act.NASH associated c←≈ irrhosis is the fastest growing i↓φndication for liver transpla₹Ωπntation in the United Stφ±"ates. Many patients with NASH→<€ develop associated liver fibroλ±sis, which can lead to complicati±¶βons such as cirrhosis and ul∏π¥timately liver failure. Whil₹βe several investigational agents targetσ mechanisms that impact the earlier stages of theβ↑ NASH continuum, Pliant is tσ argeting αvβ1, an integrin that activ®¶ates TGF-β, a putative master regulator φ of hepatic fibrosis. PLN-1474 has show¥∑λn significant inhibition of fibros&☆is in live human tissue models. Pliant eφ≤'©xpects to submit an invesσ₹¶♦tigational new drug (IND) application to the U.✔§S. Food and Drug Administration befo™₩re the end of 2019.information sour₩¥←ce:pharma focus AsiaThe original link:h §φttps://www.pharmafocusasia.com/news/pliant¶✘-therapeutics-announces-strategic-co←δ>llaboration-to-develop♦₹Ω-novel-therapies-for-nash-and-fibrotic-dε≤iseases2019 Asia-pacific pharma IP & Leader Summit: http://en.zenseegroup. ∑com/p/510934/ will be held in×↕♣∑ Beijing on November 14-15, <φ&and will attract more than 500 indu≥πstry experts from domestic♠↕ and foreign pharmaceut↔₹✔ical companies, biotechnology companies, goverβ→≈™nments, associations, law firms, int£>™ellectual property agents and other companies₹≈± to attend.Official registration↓₩ and consultation channels:Contact：AnnPhon ✔e: 021-65650305Email：Marketing@ze♣↔nseegroup.comhttp://en.zenseegroup.c<πom/p/510934 -
1024
PDS Biotechnology Complet¥®✘es Manufacturing of Clinical Ba ₽tches of PDS0101
PDS Biotechnology Completes Manufactur×α$ing of Clinical Batc®✘∑Ωhes of PDS0101WEDNESDAY, •✔'OCTOBER 23, 2019PDS Biotechn€€ology Corporation, a$←" clinical-stage immuno-®₹✔♣oncology company pioneering devel± opment of multi-functional noαλ≥vel immunotherapies, today announc←♦•↓ed that it has completed manufacturing ofΩ clinical batches of P←'™DS0101 with its partner BSP Pharmaceuti ✔cals S.p.A, a leading manufacturer of ant←₹icancer drugs.The clinical batches of PD✘↓S0101 will be used in the Company’s two upc$≥λ≥oming Phase 2 studies, which are expecte←✘÷<d to start in the first quarter of 2020.<δ The trials include a combinatiσ ©↑on study with Merck to evaluate PDS0101 i≥↓γn combination with KEYTRUDA® in first-line tre←≈atment of head and neck cancer and a sε≤☆★tudy to evaluate PDS0101 in combinat"₹₽"ion with two novel clinical-stage immunoth ↑♦erapies in advanced HPV associated cancers wiσ th the National Cancer Institute.“We are™ π pleased to have completed the manufacturing of tππhe clinical batches of PDS0101 with our p₩σartner BSP Pharmaceutical∑©Ωπs and are honored toφ↕∏♥ be collaborating with two leaders in the f÷©ield of immuno-oncology,” said Dr. Frank Bedu-∏↔Addo, CEO of PDS. “Based on our ₩recently announced Phase 1 clinical outco∑αme data which demonstrated α>£PDS0101’s unique ability to promote the in-vivo' induction of high levels of HPV-specific CD8+ λ killer T-cells as well as the r✔≥ >egression of pre-cancerous lesions in 60α☆∑% of patients, we believe that P₩>β¶DS0101 could expand the clinica €≤l efficacy of checkpoint inhibitors such as KEYTR←ΩUDA®. We are now working d♦™iligently to qualify clinical s&$¥Ωites for our combination trial wit✘>h KEYTRUDA® in first line treatment §↑↑of head and neck cancer and look fo≥★≤rward to initiating both our planned combination☆∏✘ trials by the first•₹× quarter of 2020.”information sourc±<Ω₩e:pharma focus AsiaThe original link:http$★↕s://www.pharmafocusasia.com/ne♣←ws/pds-biotechnology-completes-manufacturing♥¥↔-of-clinical-batches-of✔±₽-pds01012019 Asia-paci×Ωφ✘fic pharma IP Leader Summit: http:/✘ββ/en.zenseegroup.com/p/404716/ wi®¶∏ll be held in Beijing ←•♣on November 14-15, and will attract more tha©↔n 500 industry experts from domestic and forλ∞eign pharmaceutical companies, bi←×$otechnology companies, governments, associations,÷"πΩ law firms, intellectual property agents ✔®and other companies to attend <.Official registration and consulta✔φtion channels:Contact：AnnPhδ£one: 021-65650305Email：Marketing@zenseegro"₽up.comhttp://en.zenseegroup.com/p/510934 -
1023
Moberg Pharma and DongKo¥π o Sign Agreement for MOδδ×B-015 in the Republic of Korea
Moberg Pharma and DongKε≠←"oo Sign Agreement for MOB-01∏5 in the Republic of KoreaTUESDAY, OCTOBER • 22, 2019Moberg Pharma AB has signed ✘δ×☆a distribution agreement with DongKoo Bio ♣€σ& Pharma Co., Ltd for MOB-01₩€∞5 in the Republic of K ↑₩♥orea. Under the agreement DongKoo is gra¥≤$nted exclusive rights to market and sell §→< MOB-015 in the Republic of Korea. Mober↔♦g Pharma assumes production and supp≈&ly responsibility.DongKoo will co¶$&nduct registration activities in the Rβ↕epublic of Korea, and will be ma←¶β rketing, distributing and sel₩₽ling MOB-015 in the Republic of Korea upon comp©↕letion of registration."This is the fourth c∏♥↔∞ommercial agreement for MOB-015, this time ©§with the market leader in derma>>tology in Korea with excellent cove±•≥βrage of the dermatology clinics. We look≥α≠ forward to work with DongKoo and making§β MOB-015 available in Korea, contribu¥♥£∏ting to our vision of making MOB←•★-015 the leading nail fun×δ §gus treatment worldw✘βide", says Anna Ljung, CEO of Mobe∑♥™rg Pharma.According t•Ωo Moberg Pharma's market intelligence£∑, the Korean market for topical d'♠rugs for onychomycosis amounts to"σ $40 million (rollin≥φ♥g 12m ending June 2019).information so€↕™urce:pharma focus AsiaThe o'>riginal link:https://www.pharmafocusasia.co m/news/moberg-pharma-and-dongk₽$$oo-sign-agreement-for-✘<mob-015-in-the-republi→πc-of-korea2019 Asia-pacific pharma IP L✘♠±eader Summit: http://en.zenseeεΩgroup.com/p/510934/ φ¥≈;will be held in Beijing&nb"α•sp; on November 14-15, and will₽↕$÷ attract more than 500 industr≠≠y experts from domestic and≤×£ foreign pharmaceutical companieΩ∑s, biotechnology companies, governments, associa'∏∞¶tions, law firms, intellectual property agents™₹ and other companies to attend.Official regis&£±tration and consultati →♣on channels:Contact：AnnPhone: 021-65650305Email：πMarketing@zenseegroup.comhttp://en.zen☆₹♦seegroup.com/p/510934 -
1022
Sanofi to conduct precautionary vo ↑®Ωluntary recall of Zantac OTC in U.S α. and Canada
Sanofi to conduct precautionary voluntary rec'all of Zantac OTC in U.S. and C§☆ anadaSATURDAY, OCTOBER 19, 2019As a pr↕ecautionary measure, Sanofi ↑♠Ω™will conduct a voluntary rec®≤∏all of Zantac OTC (over-thφ₽αe-counter) in the U.S. anα∞ ÷d Canada. This recall is being φ&taken due to possible contamination w£✘εith a nitrosamine impurity called N-π☆✘nitrosodimethylamine (NDMA). The co©₽>mpany is working with health authorities ↔✔♠∑to determine the level and extent of the '✔recall.On September 13, 2019'φ, the U.S Food and Drug Administrati©φ≥on and Health Canada issued puπ↑blic statements alerting that some ranitidin'<≠e medicines, including Zantac OTC, could con£←§tain NDMA at low levels ↕←♥'and asked manufactur™ ers to conduct testi₽♥ng.Evaluations are ongoing on b₽≥∑oth drug substance (ac☆'φ tive ingredient) and finished drug product. D ₽₩ue to inconsistencies in preliminar♦☆®✔y test results of the active ingredient usε≤ed in the U.S. and Cana∏→dian products, Sanofi has madeλ" the decision to conduc φt the voluntary recal¥πl in the U.S. and Canada as the investδ ≈♥igation continues.Active ingredients used≤ε₽£ in Sanofi's ranitidine products outside of thδεe U.S. and Canada areβ€×÷ sourced from different suppliers. Sanofi is com÷™mitted to transparency ↓↓and will continue to communicate results with h&ealth authorities from the ongo&§₹ing testing, and work with them to make in←φformed decisions based on availa→≥ble data and evidence.Sanofi encourages anyone us♦™ing Zantac OTC to speak with their hea¶λlth care providers or phΩ∏armacists if they have any additional q®≈ε∑uestions.information s★ >σource:pharma focus AsiaThe ori€✔™ginal link:https:https:https://www.phar≤←mafocusasia.com/news/sano↓π♣fi-to-conduct-precautionary-voluntary-recallβ←-of-zantac-otc-in-us-and-canada2π®019 Asia-pacific pharma IP Leader ↓→Summit: http://en.zenseegroup.c"Ω♣om/p/510934/ will be heφ₽↓≠ld in Beijing on Nove♦≠mber 14-15, and will attract moreπδ§> than 500 industry experts fr>≥≥÷om domestic and foreiπ&↔gn pharmaceutical compa™βα≈nies, biotechnology companies, governmen$♠☆ts, associations, law firmsπ→♦&, intellectual property agents and othΩ βδer companies to attenεδ÷εd.Official registrat≠' ¶ion and consultation channels:δ §Contact：AnnPhone: 021-65650305Email：Marketing@γ£✘πzenseegroup.comhttp://en.zenseegroup.φ"₹•com/p/510934 -
1018
HitGen Enters into DNA-↔λβEncoded Library Based Drug Discovery Research C≠©ollaboration with Galapagos NV
HitGen Enters into DNA-E↑÷ ncoded Library Based Drug Discov♦¥♥₩ery Research Collaborati•&on with Galapagos NVTHURSDAY, OCTOBER →↔€17, 2019HitGen Inc. today ann♥✔ounced that it has entered into a drug discovery ×₽research collaboration with Galap÷↓agos NV to identify potential small molecule ∞←leads against targets o÷σ∞™f interest to Galapagos NV. In this collaboration↕∞★, HitGen will apply its technology platform,↕₽®✘ based on DNA-encoded library de∏sign, synthesis and interrogation, to discover ∞☆≥novel leads. Under the ×$☆'terms of the agreement,★Ω× HitGen will receive an undisclosed upfron♦£☆t payment and will be eligib↓εΩle for milestone payments from×≤& Galapagos NV.“We are delighted to enter this♥↑∏ collaboration with Galapagos NV, a leading b ♦γiotechnology company, specializing in t≈ he discovery and development of ↑ &small molecule medic★ines with novel modes of action. We believe€α the collaboration reinforces the role of Hitπ©↑Gen’s platform in the •®£§rapidly developing field of DNA-enco↕$ded chemistry. We will work closely with Galapa∑¥gos NV scientists to geε✘nerate new small-molecule lead compounds for theφσλ£ir research programs to help b←÷≥₹ring transformative medicines to pati∞∞₽£ents,” said Dr. Jin Li, Cha¶↔irman of the Board and Chief Executive Officer o✔♦f HitGen.“We look forward t★ o working with HitGen and tap i≈Ωnto their established DEL tec©σδhnology platform to complement our i'≈$nternal screening and drug discovery tech÷<♠δnologies.” said Romain→λ Gosmini, Director Medi≤★£©cinal Chemistry at Galapagos.informat •©ion source:pharmγ¶a focus AsiaThe original linλα→k:https:https://www.pharmafocusasia.c&¶&om/news/hitgen-enters-into-dna-encoded-libr♥÷ary-based-drug-discovery-res✔" ☆earch-collaboration-with-galapagos-nv2019 ×↓Asia-pacific pharma IP Leader Summit: http://en.zφ€<→enseegroup.com/p/510934/ will be held in&nλbsp;Beijing on Nov±☆•ember 14-15, and will attract more ≈γ£than 500 industry experts froβε✔m domestic and foreign pharmaceu&"tical companies, biotechnology companies, go®♦§vernments, associations, law firms, intelδ§♦≥lectual property agent✔ &s and other companies to attend.Officia♣✘↓l registration and consultation cha±'nnels:Contact：AnnPhone: 021-65™"×650305Email：Marketing@zenseegroup.comh☆¶≠ttp://en.zenseegroup.com/p/5109↓ 34
Contact Us
Zensee_Daystar online
© 2011-2016